Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 7/20 | 0.46 |
| ▸ | RAB9A | P51151 | 7/20 | 0.46 |
| ▸ | PKM | P14618 | 4/20 | 0.46 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.46 |
| ▸ | FGFR4 | P22455 | 2/20 | 0.46 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.46 |
| ▸ | MAOB | P27338 | 1/20 | 0.46 |
| ▸ | NFKB2 | Q00653 | 1/20 | 0.46 |
| ▸ | RELA | Q04206 | 1/20 | 0.46 |
| ▸ | MAPT | P10636 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.44 |
| ▸ | MEN1 | O00255 | 2/20 | 0.44 |
| ▸ | NAMPT | P43490 | 1/20 | 0.42 |
| ▸ | DGAT1 | O75907 | 1/20 | 0.42 |
| ▸ | LMNA | P02545 | 1/20 | 0.40 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.40 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.40 |
| ▸ | CPT2 | P23786 | 1/20 | 0.40 |
| ▸ | CPT1A | P50416 | 1/20 | 0.40 |
| ▸ | GPR142 | Q7Z601 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12415821 | 0.91 | NPC1 (0.46) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12415992 | 0.90 | MAPT (0.51) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12416028 | 0.90 | MAPT (0.47) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12507332 | 0.85 | RAB9A (0.46) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12416200 | 0.85 | FGFR4 (0.50) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12416142 | 0.85 | FGFR4 (0.51) | FGFR4MAPTDGAT1LMNARXFP1 | |
| SCHEMBL12415797 | 0.85 | FGFR4 (0.50) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12415914 | 0.84 | DGAT1 (0.48) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12416029 | 0.84 | MEN1 (0.44) | NPC1RAB9APKMSMN1; SMN2FGFR4 | |
| SCHEMBL12507328 | 0.84 | FGFR4 (0.47) | NPC1RAB9APKMSMN1; SMN2FGFR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | SHIONOGI & CO., LTD. (JP) | 2011-07-14 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110172217-A1 | RING-FUSED MORPHOLINE DERIVATIVE HAVING PI3K-INHIBITING ACTIVITY | PIK3R3, AKT3, AKT2 | NPC1 1033/4885RAB9A 346/4885PKM 1612/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.